Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients

Abstract The efficacy of anthracycline-based chemotherapeutics, which include doxorubicin and its structural relatives daunorubicin and idarubicin, remains almost unmatched in oncology, despite a side effect profile including cumulative dose-dependent cardiotoxicity, therapy-related malignancies and...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Xiaohang Qiao, Sabina Y. van der Zanden, Xiaoyang Li, Minkang Tan, Yunxiang Zhang, Ji-Ying Song, Merle A. van Gelder, Feija L. Hamoen, Lennert Janssen, Charlotte L. Zuur, Baoxu Pang, Olaf van Tellingen, Junmin Li, Jacques Neefjes
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2024-06-01
Serie:	Molecular Cancer
Soggetti:	Anthracycline Doxorubicin Aclarubicin Refractory/relapsed acute myeloid leukemia Cardiotoxicity Histone eviction
Accesso online:	https://doi.org/10.1186/s12943-024-02034-7
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!